CYBIN INC.
Business
CYBIN INC. develops and advances psychedelic-based therapeutics, focusing on psilocybin research and development. It offers clinical-stage drug candidates and associated research programs, alongside intellectual property assets related to psychedelic compounds and therapeutic platforms. Its key business segments include U.S. psilocybin research operations, an Ireland-based intellectual property and European research arm, and a U.K. subsidiary acquired to expand clinical and commercial capabilities. The company conducts research with academic and clinical research organizations and distributes its programs across North American and European markets.
Summary from filing dated 2025-07-01
Financials
Latest annual snapshot (FY2025, period end 2025-03-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-113.14M |
| Total assets | $258.62M |
| Total liabilities | — |
| Stockholders' equity | — |
| Operating cash flow | — |